SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

Completed

Conditions: Influenza

Interventions: Biological: Flublok Quadrivalent influenza vaccine RIV4
Biological: Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4

First Posted Date: 2020-07-08

Last Posted Date: 2022-05-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 96175

Registration Number: NCT04460781

Locations: 🇺🇸
Kaiser Permanente Northern California, Oakland, California, United States

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers
Influenza Immunisation

Interventions: Biological: Quadrivalent RIV with 2018-2019 NH H3 strain
Biological: Quadrivalent RIV with H3 strain 1
Biological: Quadrivalent RIV with H3 strain 2
Biological: Quadrivalent RIV with H3 strain 2 and adjuvant
Biological: Quadrivalent RIV with H3 strain 1 and adjuvant
Biological: Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant

First Posted Date: 2020-06-30

Last Posted Date: 2023-09-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 210

Registration Number: NCT04451954

Locations: 🇺🇸
Investigational Site Number 8400002, Melbourne, Florida, United States
🇺🇸
Investigational Site Number 8400003, San Diego, California, United States
🇺🇸
Investigational Site Number 8400004, Orlando, Florida, United States

and more 2 locations

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand

Phase 3

Completed

Conditions: Rotavirus Immunisation
Hepatitis B Immunisation
Haemophilus Influenzae Type B Immunisation
Pertussis Immunisation
Diphtheria Immunisation
Pneumococcal Immunisation
Polio Immunisation
Tetanus Immunisation

Interventions: Biological: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)
Biological: Human Rotavirus, live attenuated
Biological: DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)
Biological: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Biological: Inactivated Poliomyelitis Vaccine
Biological: Poliomyelitis Vaccine bivalent types 1 and 3

First Posted Date: 2020-06-12

Last Posted Date: 2022-05-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 460

Registration Number: NCT04429295

Locations: 🇹🇭
Investigational Site Number 7640001, Bangkok, Thailand
🇹🇭
Investigational Site Number 7640003, Bangkok, Thailand
🇹🇭
Investigational Site Number 7640002, Khon Kaen, Thailand

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Phase 2

Completed

Conditions: Hepatitis B Immunisation
Haemophilus Influenzae Type b Immunisation
Varicella Immunisation
Pertussis Immunisation
Polio Immunisation
Pneumococcal Immunisation
Diphtheria Immunisation
Mumps Immunisation
Tetanus Immunisation
Measles Immunisation

Interventions: Biological: Pneumococcal Conjugate Vaccine formulation 1
Biological: Pneumococcal Conjugate Vaccine formulation 2
Biological: Pneumococcal Conjugate Vaccine formulation 3
Biological: Measles, Mumps, and Rubella Virus Vaccine Live
Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
Biological: Varicella Virus Vaccine Live
Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
Biological: Hepatitis B Vaccine* [Recombinant] *as applicable

First Posted Date: 2020-05-21

Last Posted Date: 2024-11-11

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 852

Registration Number: NCT04398706

Locations: 🇺🇸
Pediatric Associates of Mt. Carmel Site Number : 8400005, Cincinnati, Ohio, United States
🇺🇸
Lincoln Pediatric Group Site Number : 8400125, Lincoln, Nebraska, United States
🇺🇸
Tribe Clinical Research Site Number : 8400025, Greenville, South Carolina, United States

and more 54 locations

Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa

Phase 4

Completed

Conditions: Poliomyelitis Vaccine
Diphtheria Immunisation
Tetanus Immunisation
Pertussis Immunisation

Interventions: Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine

First Posted Date: 2020-03-09

Last Posted Date: 2023-07-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 273

Registration Number: NCT04300192

Locations: 🇿🇦
Investigational Site Number : 7100001, Cape Town, South Africa
🇿🇦
Investigational Site Number : 7100003, Johannesburg, South Africa
🇿🇦
Investigational Site Number : 7100002, Middelburg, South Africa

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2

Phase 1

Terminated

Conditions: Genital Herpes

Interventions: Biological: HSV 2 Formulation 3
Biological: HSV 2 Formulation 1
Biological: HSV 2 Formulation 2
Biological: HSV 2 Formulation 6
Biological: HSV 2 Formulation 4
Biological: HSV 2 Formulation 5
Biological: Sodium Chloride 0.9%

First Posted Date: 2020-01-10

Last Posted Date: 2022-10-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 24

Registration Number: NCT04222985

Locations: 🇺🇸
M3 Wake Research Inc-Site Number:8400006, Raleigh, North Carolina, United States
🇺🇸
Brigham and Womens Hospital-Site Number:8400003, Boston, Massachusetts, United States
🇺🇸
Research Centers of America-Site Number:8400010, Hollywood, Florida, United States

and more 1 locations

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Quadrivalent Influenza Vaccine
Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2

First Posted Date: 2019-12-24

Last Posted Date: 2023-10-02

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 7106

Registration Number: NCT04210349

Locations: 🇨🇳
Investigational Site Number 1561001, Lincang, China
🇨🇳
Investigational Site Number 1561003, Lincang, China
🇨🇳
Investigational Site Number 1561000, Kunming, China

and more 4 locations

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

Completed

Conditions: Dengue Virus Infection

Interventions: Other: No intervention

First Posted Date: 2019-11-20

Last Posted Date: 2023-09-18

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 300

Registration Number: NCT04170140

Locations: 🇫🇷
Real World Evidence Solutions IQVIA, La Defense, France

Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Quadrivalent RIV with H3 strain 4
Biological: Quadrivalent RIV with H3 strain 3
Biological: Quadrivalent RIV with 2018-2019 NH H3 strain
Biological: Quadrivalent RIV with H3 strain 1
Biological: Quadrivalent RIV with H3 strain 2

First Posted Date: 2019-10-30

Last Posted Date: 2023-09-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 150

Registration Number: NCT04144179

Locations: 🇺🇸
Investigational Site Number 8400001, Rochester, New York, United States
🇺🇸
Investigational Site Number 8400003, Mount Pleasant, South Carolina, United States
🇺🇸
Investigational Site Number 8400002, Hollywood, Florida, United States

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

Phase 3

Completed

Conditions: Meningococcal Immunization
Healthy Volunteers

Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine
Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine
Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine
Biological: Hepatitis A vaccine
Biological: Measles, Mumps, and Rubella Virus Vaccine (MMR)
Biological: Pneumococcal 13-valent conjugate vaccine
Biological: DTwP-HepB-Hib-IPV vaccine
Biological: Varicella vaccine

First Posted Date: 2019-10-29

Last Posted Date: 2025-02-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1328

Registration Number: NCT04143061

Locations: 🇮🇳
Investigational Site Number : 3560007, Chennai, India
🇮🇳
Investigational Site Number : 3560004, Hyderabad, India
🇮🇳
Investigational Site Number : 3560011, Kolkata, India

and more 14 locations

Home Terms & Conditions Privacy Policy